This product is a fluorescent probe-based Taqman RT-PCR assay system. Firstly, the RNA of 2019-nCov will be reverse transcribed into cDNA by reverse transcriptase, and then PCR amplification will be performed with cDNA as template. During amplification of the template, the Taqman probe will be degraded due to the 5'-3’ polymerase activity and exonuclease activity of Taq DNA polymerase, then the separation of fluorescent reporter and quencher enables the fluorescent signal to be detected by instrument. The ORF1ab gene of 2019-nCoV will be detected qualitatively by FAM channel, the N gene of 2019-nCoV will be detected qualitatively by JOE channel, the E gene of 2019-nCoV will be detected qualitatively by ROX channel, and the internal reference will be detected by CY5 channel. dUTP and UNG enzyme are used in the kit to prevent contamination of the amplified products. Internal reference is used in the kit for quality control starting from sample collection.
【PRODUCT NAME】 2019-Novel Coronavirus (2019-nCoV) RT-PCR Detection Kit
【SIZE】 32 tests/kit, 48 tests/kit, 96 tests/kit
【INTENDED USE】 This product is intended for the rapid detection of 2019-nCOV in human throat swab or sputum samples. Coronavirus is a +ssRNA virus with envelope. Its diameter is about 80-120 nm. Its genetic material is the largest of all RNA viruses. It is an important pathogen of many livestock, pets, including human diseases, and can cause many kinds of acute and chronic diseases. According to Virus Taxonomy- Ninth Report of the International Committee on Taxonomy of Viruses, the Coronaviridae is divided into three genera: α, β and γ. Among them, α Coronavirus (such as human Coronavirus 229E, human Coronavirus NL63), β Coronavirus (such as human Coronavirus HKU1, human Coronavirus OC43 and SARS) can cause disease of varying degree to human. The common signs of people infected with coronavirus are respiratory symptoms, fever, cough, shortness of breath and dyspnea. In more serious cases, infection can lead to pneumonia, severe acute respiratory syndrome, renal failure, and even death. The "2019-nCoV" was named by WHO in January 12, 2020. According to the confirmed case request in New Coronavirus Pneumonia Prevention and Control Program (6th ed), clinical diagnosis case or suspected case has the following pathogenic evidences: RT-PCR detection result of 2019-nCOV in respiratory tract or blood sample is posit